What effect has the SYNTAX trial had on practice in Europe? Philippe Kolh reviews the trial and its guidelines.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Coronary Disease - Surgery
June 11, 2016
The authors compare single-institution retrospective data on outcomes of coronary bypass grafting or PCI for isolated CAD in over 12,000 pts. Overall survival was better for PCI patients (46% vs 34% at 15 yrs). However, survival for patients undergoing CABG with multiple arterial grafts was superior to most other interventions at 15 years and was s
May 8, 2016
A collaborative multi-funded RCT by Chinese surgeons and European epidemiologists, this article is guaranteed to elicit thunderous responses from biomedical publishing and the pharmaceutical industry.
April 23, 2016
An editorial discussion of the impressive 10-year benefits of CABG for ischemic cardiomyopathy as found in the STICH trial.
April 3, 2016
In a propensity-matched analysis, Rosenblum and colleagues found that hybrid revascularization as compared with coronary artery bypass grafting with either single or bilateral internal mammary artery grafts was superior in terms of secondary short-term outcomes (e.g.
March 22, 2016
This retrospective study evaluated the relationship between the timing betweenLHC and CABG and its effect on renal function in a cohort of 2371 patients at a single center. Findings included:
March 14, 2016
The Hopkins group reviewed differential outcomes in close to 800 patients who had undergone bilateral IMA revascularization during CABG. The compared configurations included:
March 13, 2016
The authors reviewed the Medicare database to analyze the trends in CABG surgery within this population over a 12-year period. Trends in the Medicare population included the following:
March 11, 2016
The authors provide an excellent overview of the rationale for screening all patients with a new diagnosis of cardiomyopathy for coronary artery disease. This rationale includes the following:
February 28, 2016
In this trial 2100 undergoing coronary surgery were randomized to aspirin 100mg or placebo. The primary outcome was defined as a composite of death and thrombotic complications (myocardial infarction, stroke, pulmonary embolism, renal failure or bowel infarction) at 30 days.